DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts

B. C. Giovanella, J. S. Stehlin, M. E. Wall, M. C. Wani, A. W. Nicholas, Leroy-Fong Liu, R. Silber, M. Potmesil

Research output: Contribution to journalArticle

659 Citations (Scopus)

Abstract

Drug development is needed to improve chemotherapy of patients with locally advanced or metastratic colon carcinoma, who otherwise have an unfavorable prognosis. DNA topoisomerase I, a nuclear enzyme important for solving topological problems arising during DNA replication and for other cellular functions, has been identified as a principal target of a plant alkaliod 20(S)-camptothecin. Signficantly increased concentrations of this enzyme, compared to that in normal colonic mucosa, were found in advanced stages of human colon adenocarcinoma and in xenografts of colon cancer carried by immunodeficient mice. Several synthetic analogs of camptothecin, selected by tests with the purified enzyme and tissue-culture screens, were evaluated in the xenograft model. Unlike other anticancer drugs tested, 20(RS)-9-amino-camptothecin (9-AC) induced disease-free remissions. The overall drug toxicity was low and allowed for repeated courses of treatment.

Original languageEnglish
Pages (from-to)1046-1048
Number of pages3
JournalScience
Volume246
Issue number4933
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

Camptothecin
Type I DNA Topoisomerase
Heterografts
Colonic Neoplasms
Drug Therapy
Colon
Enzymes
Drug-Related Side Effects and Adverse Reactions
DNA Replication
Pharmaceutical Preparations
Mucous Membrane
Adenocarcinoma
Carcinoma
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L-F., ... Potmesil, M. (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246(4933), 1046-1048.

DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. / Giovanella, B. C.; Stehlin, J. S.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Liu, Leroy-Fong; Silber, R.; Potmesil, M.

In: Science, Vol. 246, No. 4933, 1989, p. 1046-1048.

Research output: Contribution to journalArticle

Giovanella, BC, Stehlin, JS, Wall, ME, Wani, MC, Nicholas, AW, Liu, L-F, Silber, R & Potmesil, M 1989, 'DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts', Science, vol. 246, no. 4933, pp. 1046-1048.
Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu L-F et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 1989;246(4933):1046-1048.
Giovanella, B. C. ; Stehlin, J. S. ; Wall, M. E. ; Wani, M. C. ; Nicholas, A. W. ; Liu, Leroy-Fong ; Silber, R. ; Potmesil, M. / DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. In: Science. 1989 ; Vol. 246, No. 4933. pp. 1046-1048.
@article{8186aa3f1093405bb39eff4f79ae5973,
title = "DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts",
abstract = "Drug development is needed to improve chemotherapy of patients with locally advanced or metastratic colon carcinoma, who otherwise have an unfavorable prognosis. DNA topoisomerase I, a nuclear enzyme important for solving topological problems arising during DNA replication and for other cellular functions, has been identified as a principal target of a plant alkaliod 20(S)-camptothecin. Signficantly increased concentrations of this enzyme, compared to that in normal colonic mucosa, were found in advanced stages of human colon adenocarcinoma and in xenografts of colon cancer carried by immunodeficient mice. Several synthetic analogs of camptothecin, selected by tests with the purified enzyme and tissue-culture screens, were evaluated in the xenograft model. Unlike other anticancer drugs tested, 20(RS)-9-amino-camptothecin (9-AC) induced disease-free remissions. The overall drug toxicity was low and allowed for repeated courses of treatment.",
author = "Giovanella, {B. C.} and Stehlin, {J. S.} and Wall, {M. E.} and Wani, {M. C.} and Nicholas, {A. W.} and Leroy-Fong Liu and R. Silber and M. Potmesil",
year = "1989",
language = "English",
volume = "246",
pages = "1046--1048",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4933",

}

TY - JOUR

T1 - DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts

AU - Giovanella, B. C.

AU - Stehlin, J. S.

AU - Wall, M. E.

AU - Wani, M. C.

AU - Nicholas, A. W.

AU - Liu, Leroy-Fong

AU - Silber, R.

AU - Potmesil, M.

PY - 1989

Y1 - 1989

N2 - Drug development is needed to improve chemotherapy of patients with locally advanced or metastratic colon carcinoma, who otherwise have an unfavorable prognosis. DNA topoisomerase I, a nuclear enzyme important for solving topological problems arising during DNA replication and for other cellular functions, has been identified as a principal target of a plant alkaliod 20(S)-camptothecin. Signficantly increased concentrations of this enzyme, compared to that in normal colonic mucosa, were found in advanced stages of human colon adenocarcinoma and in xenografts of colon cancer carried by immunodeficient mice. Several synthetic analogs of camptothecin, selected by tests with the purified enzyme and tissue-culture screens, were evaluated in the xenograft model. Unlike other anticancer drugs tested, 20(RS)-9-amino-camptothecin (9-AC) induced disease-free remissions. The overall drug toxicity was low and allowed for repeated courses of treatment.

AB - Drug development is needed to improve chemotherapy of patients with locally advanced or metastratic colon carcinoma, who otherwise have an unfavorable prognosis. DNA topoisomerase I, a nuclear enzyme important for solving topological problems arising during DNA replication and for other cellular functions, has been identified as a principal target of a plant alkaliod 20(S)-camptothecin. Signficantly increased concentrations of this enzyme, compared to that in normal colonic mucosa, were found in advanced stages of human colon adenocarcinoma and in xenografts of colon cancer carried by immunodeficient mice. Several synthetic analogs of camptothecin, selected by tests with the purified enzyme and tissue-culture screens, were evaluated in the xenograft model. Unlike other anticancer drugs tested, 20(RS)-9-amino-camptothecin (9-AC) induced disease-free remissions. The overall drug toxicity was low and allowed for repeated courses of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0024358188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024358188&partnerID=8YFLogxK

M3 - Article

VL - 246

SP - 1046

EP - 1048

JO - Science

JF - Science

SN - 0036-8075

IS - 4933

ER -